Brean Capital reiterated its Sell rating on Rockwell Medical Inc (NASDAQ: RMTI) on Monday following the FDA approval of its Triferic iron replacement product.
The firm maintained a $4 price target.
Analysts Jonathan Aschoff and Yi Cheng...
Rockwell Medical has overcome some hard questions and lingering doubts about its iron-replacement drug for dialysis patients, winning a long-sought FDA approval for Triferic and providing the biotech a green light to begin its marketing campaign.
Oops! Unable to complete your request. Please refresh your browser.
Companies in this industry provide dialysis services to patients with diabetes. These companies make a substantial portion of their revenue from prescribing diabetes drugs. They also heavily dependent on Medicare and Medicaid.